Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 7/20 | 0.52 |
| ▸ | PGK2 | P07205 | 7/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 2/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ACP3 | P15309 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14354093 | 0.90 | PGK1 (0.47) | PGK1PGK2CA2CA4CA5A | |
| SCHEMBL28898511 | 0.88 | FBP1 (0.48) | PGK1PGK2CA2CA4CA5A | |
| SCHEMBL28146410 | 0.85 | KEAP1 (0.55) | PGK1PGK2CA2CA4CA5A | |
| SCHEMBL8389841 | 0.85 | PGK1 (0.44) | PGK1PGK2CA2CA4CA5A | |
| SCHEMBL28212727 | 0.85 | PGK1 (0.50) | PGK1PGK2CA2CA4CA5A | |
| SCHEMBL7595631 | 0.85 | PGK1 (0.50) | PGK1PGK2CA2CA4CA5A | |
| SCHEMBL27552157 | 0.83 | PGK1 (0.49) | PGK1PGK2CA2CA4CA5A | |
| SCHEMBL13174968 | 0.83 | PGK1 (0.53) | PGK1PGK2CA2CA4CA5A | |
| SCHEMBL6262029 | 0.81 | CA2 (0.65) | PGK1PGK2CA2CA4CA5A | |
| SCHEMBL21585512 | 0.80 | AKR1B1 (0.52) | PGK1PGK2CA2CA4CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553809-B2 | Fc receptor modulators and uses thereof | ILEXUS PTY LIMITED (AU) | 2009-06-30 | — | — | US | disclosed |
| US-7553809-B2 | Fc receptor modulators and uses thereof | ILEXUS PTY LIMITED (AU) | 2009-06-30 | — | — | US | disclosed |
| US-20060057144-A1 | Fc receptor modulators and uses thereof | ILEXUS PTY LIMITED (AU) | 2006-03-16 | — | — | US | disclosed |
| US-6835753-B2 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | ILEXUS PTY LIMITED (AU) | 2004-12-28 | — | — | US | disclosed |
| EP-1109545-A4 | Fc RECEPTOR MODULATORS AND USES THEREOF | ILEXUS PTY LTD (AU) | 2004-11-10 | — | — | EP | disclosed |
| US-20020061844-A1 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | ILEXUS PTY LIMITED | 2002-05-23 | — | — | US | disclosed |
| US-6355683-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE | ILEXUS PTY LIMITED (AU) | 2002-03-12 | — | — | US | disclosed |
| EP-1109545-A1 | Fc RECEPTOR MODULATORS AND USES THEREOF | ILEXUS PTY LTD (AU) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000015214-A1 | Fc RECEPTOR MODULATORS AND USES THEREOF | ILEXUS PTY LIMITED (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061844-A1 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | FCGR2A, FCGR1A, FCER2 | PGK1 4477/4885PGK2 4430/4885CA2 851/4885 |
| US-20060057144-A1 | Fc receptor modulators and uses thereof | FCGR1A, FCER2, FCGR2A | PGK1 4171/4885PGK2 3969/4885CA2 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.